GSK (LON:GSK – Get Free Report) had its target price raised by investment analysts at Barclays from GBX 1,450 ($18.15) to GBX 1,575 ($19.71) in a note issued to investors on Monday, FlyOnTheWall reports. Barclays‘s price objective points to a potential upside of 4.43% from the stock’s current price.
A number of other equities analysts have also weighed in on GSK. Shore Capital reissued a “buy” rating on shares of GSK in a research report on Friday, June 16th. Berenberg Bank reissued a “buy” rating and set a GBX 1,730 ($21.65) price target on shares of GSK in a research note on Friday, July 28th. Jefferies Financial Group reaffirmed a “hold” rating and issued a GBX 1,575 ($19.71) price objective on shares of GSK in a research report on Monday, June 26th. Citigroup reiterated a “neutral” rating and set a GBX 1,700 ($21.27) target price on shares of GSK in a research report on Monday, June 26th. Finally, Bank of America cut their target price on GSK from GBX 1,450 ($18.15) to GBX 1,390 ($17.39) in a research report on Monday, July 17th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of GBX 1,572.50 ($19.68).
GSK Price Performance
Insiders Place Their Bets
In other news, insider Jonathan Symonds bought 6,000 shares of the business’s stock in a transaction on Friday, June 23rd. The stock was purchased at an average cost of GBX 1,440 ($18.02) per share, for a total transaction of £86,400 ($108,121.64). In other news, insider Jonathan Symonds bought 6,000 shares of the stock in a transaction that occurred on Friday, June 23rd. The shares were purchased at an average cost of GBX 1,440 ($18.02) per share, with a total value of £86,400 ($108,121.64). Also, insider Hal Barron sold 19,446 shares of the business’s stock in a transaction dated Thursday, August 24th. The stock was sold at an average price of GBX 3,462 ($43.32), for a total transaction of £673,220.52 ($842,473.43). In the last three months, insiders have purchased 6,018 shares of company stock worth $8,664,147. 1.74% of the stock is owned by corporate insiders.
GSK plc, together with its subsidiaries, engages in the research, development and manufacture of vaccines and specialty medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare.
- Five stocks we like better than GSK
- Earnings Per Share Calculator: How to Calculate EPS
- 2 Recession-Proof Intelligence Stocks to Defend Your Portfolio
- CD Calculator: Certificate of Deposit Calculator
- 5 Reasons Mullen Automotive is About to Turn a Corner
- P/E Ratio Calculation: How to Assess Stocks
- Qualcomm and Apple Forge Ahead with New Modem Partnership
Receive News & Ratings for GSK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GSK and related companies with MarketBeat.com's FREE daily email newsletter.